fluocinolone/tretinoin/hydroquinone (Rx)

Brand and Other Names:Tri-Luma
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

fluocinolone/tretinoin/hydroquinone

cream

  • (0.01%/0.05%/4%)/30g

Melasma

Indicated for short-term treatment of moderate to severe melasma

Apply to face qHS, at least 30 min before bedtime

Wash face gently before application; rinse & pat dry

Apply thin film of Tri-Luma to hyperpigmented area & 1/2 inch surrounding skin

Do not use occlusive dressing

Safety & efficacy not established

Next:

Interactions

Interaction Checker

and fluocinolone/tretinoin/hydroquinone

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (0)

                Monitor Closely (0)

                  Minor (0)

                    Previous
                    Next:

                    Adverse Effects

                    >10%

                    Erythema (41-45%)

                    Desquamation (36-40%)

                    Burning (16-20%)

                    Dryness (11-15%)

                    Pruritis (11-15%)

                    1-10%

                    Acne (5%)

                    Telangiectasia (3%)

                    Hyperesthesia (2%)

                    Rosacea (1%)

                    Vesicles (1%)

                    Xerostomia (1%)

                    Paresthesia (3%)

                    <1%

                    Acneiform

                    Eruptions

                    HPA axis suppression

                    Hypopigmentation

                    Itching

                    Ochronosis

                    Miliaria

                    Skin atrophy

                    Perioral dermatitis

                    Previous
                    Next:

                    Warnings

                    Contraindications

                    Hypersensitivity

                    Cautions

                    Not indicated for maintenance treatment of melasma

                    Avoid sun exposure

                    Safety & efficacy of Tri-Luma in patients of skin types V and VI not studied. Excessive bleaching in pts with darker skin cannot be excluded.

                    Safety & efficacy in treatment of hyperpigmentation conditions other than melasma of face not studied

                    Contains sodium matabisulfite which may cause allergic-type reactions in susceptible pts.

                    Hydroquinone may produce exogenous ochronosis (darkening of skin)- promptly discontinue if occurs

                    Previous
                    Next:

                    Pregnancy & Lactation

                    Pregnancy Category: C

                    Lactation: not known whether excreted in breast milk; use caution

                    Pregnancy Categories

                    A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                    B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                    C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                    D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                    X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                    NA: Information not available.

                    Previous
                    Next:

                    Pharmacology

                    Absorbed: minimal

                    Mechanism of Action

                    Hydroquinone: Inhibits melanocyte metabolic processes that produce melanin; incr excretion of melanin from melanocytes

                    Fluocinolone: Corticosteroids decrease inflammation by stabilizing leukocyte lysosomal membranes

                    Tretinoin: Follicular epithelium irritant

                    Previous
                    Next:

                    Images

                    No images available for this drug.
                    Previous
                    Next:

                    Patient Handout

                    A Patient Handout is not currently available for this monograph.
                    Previous
                    Next:

                    Formulary

                    FormularyPatient Discounts

                    Adding plans allows you to compare formulary status to other drugs in the same class.

                    To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

                    Adding plans allows you to:

                    • View the formulary and any restrictions for each plan.
                    • Manage and view all your plans together – even plans in different states.
                    • Compare formulary status to other drugs in the same class.
                    • Access your plan list on any device – mobile or desktop.

                    The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

                    Tier Description
                    1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
                    2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
                    3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
                    4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                    5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                    6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                    NC NOT COVERED – Drugs that are not covered by the plan.
                    Code Definition
                    PA Prior Authorization
                    Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
                    QL Quantity Limits
                    Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
                    ST Step Therapy
                    Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
                    OR Other Restrictions
                    Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
                    Additional Offers
                    Email to Patient

                    From:

                    To:

                    The recipient will receive more details and instructions to access this offer.

                    By clicking send, you acknowledge that you have permission to email the recipient with this information.

                    Email Forms to Patient

                    From:

                    To:

                    The recipient will receive more details and instructions to access this offer.

                    By clicking send, you acknowledge that you have permission to email the recipient with this information.

                    Previous
                    Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.